
nanoView Diagnostics Inc (AKA: Nanoview Biosciences) Profile last edited on: 7/16/2023
CAGE: 7EBE8
UEI: ----------
Business Identifier: Nanoparticle detection platform for complex human sample analysis Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Suffolk
Congr. District: 07
County: Suffolk
Public Profile
nanoView Diagnostics Inc. (also dba NanoView Biosciences) is an early stage firm developing technologies for the detection and characterization of biofluid based nanoparticles, i.e. extracellular vesicles (EVs) and exosomes. EVs are being studied for diagnostic and therapeutic applications in high-impact areas like neurodegerative disease, cardiovascular disease, and cancer. Enabling simple detection of nanoparticles from complex samples like whole blood, serum, plasma, and urine, the VDXs developed technology simplifies the analysis and characterization of EVs as they are prepared for therapeutics or for use as an early biomarker of disease. Developing proprietary products that support research, translation and delivery of precision medicine, the Company' high-throughput, cost-effective analysis solutions enable life science researchers tbetter to understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 2 | NSF | $1,159,243 | |
Project Title: High-Throughput Nanoparticle Characterization for Life Sciences Applications | ||||
2021 | 1 | NIH | $351,922 | |
Project Title: Single Vesicle Phenotyping of Circulating Exosomes Carrying Immunomodulatory Markers for Therapy Selection and Monitoring. | ||||
2018 | 1 | NIH | $227,001 | |
Project Title: A Scalable Blood-based Pancreatic Cancer Test for High-Risk Screening |
Key People / Management
George Daaboul -- Co-Founder, President and CSO
David Freedman -- President and COO
Jerry Williamson -- CEO
Amanda Barbou -- Assay Development Scientist
Michael Creighton -- VP of Finance
Aditya Dhande -- Research Associate
Andrew Malloy -- VP of Sales & Marketing
Gabriel Reznik -- Senior Scientist
David Freedman -- President and COO
Jerry Williamson -- CEO
Amanda Barbou -- Assay Development Scientist
Michael Creighton -- VP of Finance
Aditya Dhande -- Research Associate
Andrew Malloy -- VP of Sales & Marketing
Gabriel Reznik -- Senior Scientist
Company News
There are no news available.